250 related articles for article (PubMed ID: 20833872)
1. Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation.
Chen P; Véricel E; Lagarde M; Guichardant M
FASEB J; 2011 Jan; 25(1):382-8. PubMed ID: 20833872
[TBL] [Abstract][Full Text] [Related]
2. Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation.
Chen P; Fenet B; Michaud S; Tomczyk N; Véricel E; Lagarde M; Guichardant M
FEBS Lett; 2009 Nov; 583(21):3478-84. PubMed ID: 19818771
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes.
Serhan CN; Gotlinger K; Hong S; Lu Y; Siegelman J; Baer T; Yang R; Colgan SP; Petasis NA
J Immunol; 2006 Feb; 176(3):1848-59. PubMed ID: 16424216
[TBL] [Abstract][Full Text] [Related]
4. Structure-function relationships of non-cyclic dioxygenase products from polyunsaturated fatty acids: poxytrins as a class of bioactive derivatives.
Lagarde M; Véricel E; Liu M; Chen P; Guichardant M
Biochimie; 2014 Dec; 107 Pt A():91-4. PubMed ID: 25223888
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory and anti-virus potential of poxytrins, especially protectin DX.
Lagarde M; Guichardant M; Bernoud-Hubac N
Biochimie; 2020 Dec; 179():281-284. PubMed ID: 32956736
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
7.
Tsai WC; Kalyanaraman C; Yamaguchi A; Holinstat M; Jacobson MP; Holman TR
Biochemistry; 2021 Jun; 60(22):1741-1754. PubMed ID: 34029049
[TBL] [Abstract][Full Text] [Related]
8. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition.
Pace-Asciak CR; Reynaud D; Demin P; Aslam R; Sun A
J Pharmacol Exp Ther; 2002 May; 301(2):618-24. PubMed ID: 11961065
[TBL] [Abstract][Full Text] [Related]
9. The effects of oxidation products of arachidonic acid and n3 fatty acids on vascular and platelet function.
Barden A; Mas E; Henry P; Durand T; Galano JM; Roberts LJ; Croft KD; Mori TA
Free Radic Res; 2011 Apr; 45(4):469-76. PubMed ID: 21235285
[TBL] [Abstract][Full Text] [Related]
10. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid-derived lipid mediators and blood platelet aggregation.
Lagarde M; Chen P; Véricel E; Guichardant M
Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):227-30. PubMed ID: 20207119
[TBL] [Abstract][Full Text] [Related]
12. Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A2/prostaglandin H2 receptor in human platelets.
Swann PG; Venton DL; Le Breton GC
FEBS Lett; 1989 Jan; 243(2):244-6. PubMed ID: 2537230
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
[TBL] [Abstract][Full Text] [Related]
14. Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation.
Akiba S; Murata T; Kitatani K; Sato T
Biol Pharm Bull; 2000 Nov; 23(11):1293-7. PubMed ID: 11085354
[TBL] [Abstract][Full Text] [Related]
15. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
[TBL] [Abstract][Full Text] [Related]
16. DHA metabolism: targeting the brain and lipoxygenation.
Picq M; Chen P; Perez M; Michaud M; Véricel E; Guichardant M; Lagarde M
Mol Neurobiol; 2010 Aug; 42(1):48-51. PubMed ID: 20422316
[TBL] [Abstract][Full Text] [Related]
17. Effect of polyunsaturated fatty acids and their metabolites on bleomycin-induced cytotoxic action on human neuroblastoma cells in vitro.
Polavarapu S; Mani AM; Gundala NK; Hari AD; Bathina S; Das UN
PLoS One; 2014; 9(12):e114766. PubMed ID: 25536345
[TBL] [Abstract][Full Text] [Related]
18. 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor.
Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Heikes JE; Sprague PW; Antonaccio MJ
Prostaglandins; 1981 Aug; 22(2):295-307. PubMed ID: 6270744
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet effect of catechol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.
Chang MC; Chang HH; Wang TM; Chan CP; Lin BR; Yeung SY; Yeh CY; Cheng RH; Jeng JH
PLoS One; 2014; 9(8):e104310. PubMed ID: 25122505
[TBL] [Abstract][Full Text] [Related]
20. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation.
Mas E; Croft KD; Zahra P; Barden A; Mori TA
Clin Chem; 2012 Oct; 58(10):1476-84. PubMed ID: 22912397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
